RenovoRx (RNXT) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
RenovoRx (RNXT) has outperformed Talphera (TLPH) over the past year, gaining 9.9% versus a loss of 18.2%. Over five years, RNXT leads with a -77.8% price change compared with -94.7% for TLPH. RenovoRx is the larger company by market cap ($58.3 million vs $55.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNXT | TLPH |
|---|---|---|
| Share price | $1.29 | $1.08 |
| Market cap | $58.28M | $55.80M |
| 1-day change | -2.89% | -0.46% |
| YTD return | +58.33% | -5.26% |
| 1-year return | +9.92% | -18.18% |
| 5-year return | -77.76% | -94.71% |
| EPS (TTM) | $-0.31 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.59 | $1.57 |
| 52-week low | $0.701 | $0.69 |
| Distance from 52-week high | -50.14% | -31.53% |
| Analyst consensus | none | none |
| Avg. price target upside | +452.07% | +191.16% |
| Average volume | 765.87K | 238.38K |
| Shares outstanding | 45.13M | 51.91M |
| Employees | 17 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed TLPH by 28.1 percentage points over the past year.
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
RNXT vs TLPH FAQ
Which is bigger, RenovoRx or Talphera?
RenovoRx (RNXT) is larger, with a market capitalization of $58.28M compared with $55.80M for Talphera (TLPH).
Which stock has performed better over the past year, RNXT or TLPH?
RNXT returned +9.92% over the past 12 months, compared with -18.18% for TLPH (price return, excluding dividends). Past performance does not predict future results.
Are RenovoRx and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.